Every Form 4 that Orchestra BioMed Holdings, Inc. (OBIO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow OBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OBIO filings page.
Orchestra BioMed Holdings, Inc. President and Chief Operating Officer Darren Sherman sold 15,000 shares of common stock on October 1, 2026, at a weighted average price of $6.36 per share. The sales were made under a Rule 10b5-1 trading plan adopted December 18, 2025; prices ranged from $6.20 to $6.48. Sherman directly held 1,119,402 shares after the sale. A separate 2,000-share holding was reported indirectly through his son, and Sherman disclaimed beneficial ownership of those securities.
Orchestra BioMed Holdings, Inc. (OBIO) reported that Chief Executive Officer and Chairperson David P. Hochman had 6,566 shares of Common Stock withheld on September 10, 2026 to satisfy tax withholding obligations upon vesting of restricted stock units. According to the disclosure, no shares were sold in the market in connection with this event.
After these tax-withholding transactions, Hochman held 1,067,463 shares directly and 432,916 shares indirectly through the DPH 2008 Trust, as well as additional indirect holdings through several family trusts. No Rule 10b5-1 trading plan is reported for these transactions.
Orchestra BioMed Holdings, Inc. (OBIO) reported that Chief Executive Officer and Chairperson David P. Hochman purchased 10,000 shares of common stock on September 3, 2026 in an open-market or private transaction at a weighted average price of $4.79 per share, with individual prices ranging from $4.73 to $4.79. Following this purchase, he directly holds 1,070,746 common shares, in addition to several indirect holdings through family trusts.
Orchestra BioMed Holdings, Inc. (OBIO) insider Darren Sherman, President, Chief Operating Officer and director, reported a sale of 15,000 shares of Common Stock on September 1, 2026 at a weighted average price of $4.94 per share, in open-market or private transactions executed under a Rule 10b5-1 trading plan adopted on December 18, 2025. Following this sale, he directly holds 1,134,402 shares of Common Stock. A separate indirect holding of 2,000 shares is reported as held by his son, for which he disclaims beneficial ownership.
Orchestra BioMed Holdings, Inc. (OBIO) reported that Chief Financial Officer Andrew Taylor Lawrence had 3,076 shares of common stock withheld on 2026-08-26 to satisfy tax withholding obligations related to vesting of restricted stock units. The filing states that no shares were sold in the market. Following this tax-withholding transaction, Lawrence directly holds 589,989 shares of OBIO common stock.
For Orchestra BioMed Holdings, Inc. (OBIO), President and Chief Operating Officer Darren Sherman reported two transactions in Common Stock on August 26, 2026. First, 4,925 shares were withheld by the company at $5.26 per share to satisfy tax withholding obligations upon vesting of restricted stock units, leaving 1,149,402 shares held directly; no shares were sold in the market for this event. Second, an account held by Mr. Sherman’s son purchased 2,000 shares at $5.33 per share, reported as indirect ownership, but Mr. Sherman disclaims beneficial ownership of those shares.
Orchestra BioMed Holdings, Inc. (OBIO) reported an insider equity event involving Principal Accounting Officer Joshua Aiello. On 2026-08-26, 203 shares of common stock were withheld at $5.26 per share to satisfy tax withholding obligations upon vesting of restricted stock units. No shares were sold in the market, and Aiello now holds 18,441 shares of common stock directly.
Orchestra BioMed Holdings director David Pacitti reported a single transaction involving company stock. On 2026-08-12, 3,761 shares of common stock were withheld at $4.42 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units. According to the company’s disclosure, no shares were sold in the market in connection with this event. After this withholding, Pacitti’s directly held stake totaled 54,750 shares of common stock.
Orchestra BioMed Holdings, Inc. director Eric S. Fain reported an indirect disposition of 5,145 shares of common stock on 2026-08-12. The shares, held by The Fain Living Trust, were withheld by the company to cover tax withholding obligations arising from vesting of restricted stock units. No shares were sold in the market, and the trust’s indirect holdings after this event were 99,630 shares.
Orchestra BioMed Holdings, Inc. director John Prosper Mack reported a Form 4 transaction where 4,885 shares of common stock were withheld by the company at $4.42 per share to satisfy tax withholding obligations upon vesting of restricted stock units. According to the company, no shares were sold in the market, and Mack’s directly held stake after the withholding is 66,544 shares.
Orchestra BioMed Holdings, Inc. director Chris Cleary reported a Form 4 transaction involving 4,238 shares of common stock on August 12, 2026. The shares were withheld by the company solely to satisfy tax withholding obligations upon vesting of restricted stock units, with no shares sold in the market. Following this withholding, Cleary directly holds 29,153 common shares.
Orchestra BioMed Holdings, Inc. executive Darren Sherman reported selling 15,000 shares of common stock on August 3, 2026 at a weighted average price of $4.09 per share, in trades ranging from $3.94 to $4.15, under a Rule 10b5-1 trading plan adopted on December 18, 2025. Following the sale, he directly held 1,154,327 shares.
Orchestra BioMed Holdings director and officer Darren Sherman sold 15,000 shares of common stock in an open-market sale. The transaction occurred at a weighted average price of about $4.27 per share, with individual sale prices ranging from $4.21 to $4.32.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025. After this transaction, Sherman directly holds 1,169,327 shares, indicating he retains a substantial continuing stake in Orchestra BioMed.
Orchestra BioMed Holdings director compensation and tax withholding activity was reported through the Fain Living Trust. On June 23, 2026, the trust received 17,327 shares of Common Stock as a grant of restricted stock units, each representing one future share subject to service-based vesting after one year.
On the same date, the trust was granted 21,277 stock options with an exercise price of $4.04 per share, expiring on June 23, 2036, which also vest after one year of continuous service. On June 24, 2026, 4,261 shares were withheld by the issuer to cover tax obligations upon RSU vesting, with no market sale of shares. Following these transactions, the trust held 104,775 shares of Common Stock indirectly for the reporting person.
Orchestra BioMed Holdings director David Pacitti reported compensation-related equity awards and a routine tax withholding. On June 23, 2026, he received 17,327 restricted stock units, each representing one future share of common stock, and a stock option for 21,277 shares at an exercise price of $4.04 per share. Both the RSUs and options vest on the one-year anniversary of the grant date, contingent on his continued service. On June 24, 2026, 3,784 shares were withheld by the company to cover tax obligations upon RSU vesting, with no shares sold in the market. Following these transactions, he directly holds 58,511 common shares and holds options for 21,277 additional shares.
Orchestra BioMed Holdings director Chris Cleary reported compensation-related equity transactions. On this Form 4, 3,510 shares of common stock were disposed of through share withholding to cover tax obligations tied to vesting of restricted stock units, and no shares were sold in the market. After this tax-withholding disposition, Cleary directly holds 33,391 common shares.
He also received a grant of stock options for 42,553 shares of common stock at an exercise price of $4.04 per share, expiring on June 23, 2036. According to the footnote, these options will vest on the one-year anniversary of June 23, 2026, subject to his continuous service with the company.
Orchestra BioMed Holdings, Inc. director Pamela Ann Connealy received equity compensation in the form of restricted stock units and stock options. She was granted 17,327 RSUs, each representing one future share of Common Stock, which vest on the one-year anniversary of the June 23, 2026 grant date, subject to continued service.
She also received stock options for 21,277 shares of Common Stock at an exercise price of $4.0400 per share, expiring on June 23, 2036, which vest on the same one-year schedule. Following the RSU award, her direct Common Stock holdings total 66,038 shares.
Orchestra BioMed Holdings director Aryeh Jason received a new stock option grant. The award covers 42,553 options to buy Common Stock at an exercise price of $4.04 per share, with no cash paid at grant.
The options were granted on June 23, 2026 and will vest on the one-year anniversary of the June 23, 2026 grant date, as long as Jason continues to serve the company through that date. After this award, he holds 42,553 options directly, and there were no share sales or open-market purchases reported in this filing.
Orchestra BioMed Holdings, Inc. director John Prosper Mack reported routine equity compensation activity involving restricted stock units (RSUs). On the grant date, he received 34,653 RSUs, each representing one future share of common stock, vesting after one year of continued service.
When previously granted RSUs vested, 3,510 shares were withheld by the company to cover tax obligations, with no shares sold in the market. Following these transactions, he holds 71,429 shares of common stock directly.
Orchestra BioMed Holdings, Inc. Chief Financial Officer Andrew Taylor Lawrence reported a tax-related share withholding linked to restricted stock unit vesting. The issuer withheld 36,352 shares of common stock at an implied value of $4.02 per share to satisfy tax withholding obligations, and no shares were sold in the market. After this withholding, Lawrence directly holds 593,065 shares of Orchestra BioMed common stock.
Orchestra BioMed Holdings, Inc. director and officer David P. Hochman reported routine equity compensation activity tied to vesting of restricted stock units. On June 10, 2026, the issuer withheld a total of 6,566 shares of Common Stock at $4.02 per share to satisfy tax withholding obligations, with no shares sold in the market.
After these tax-withholding dispositions, Hochman holds 1,060,746 Common Stock shares directly and 436,199 shares indirectly through the DPH 2008 Trust, along with additional indirect holdings in several family trusts holding between 2,000 and 3,140 shares each.
Orchestra BioMed Holdings, Inc. director and officer David P. Hochman reported an open-market purchase of 5,000 shares of Common Stock on June 1, 2026 at a weighted average price of $3.83 per share. After this transaction, he directly holds 1,064,029 shares of Common Stock.
Additional shares are held indirectly through various family trusts, including 439,482 shares held by the DPH 2008 Trust and smaller positions held by several 2008 and 2019 family trusts.
Orchestra BioMed Holdings director and officer Darren Sherman reported selling 15,000 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $3.87 per share, in multiple trades between $3.81 and $4.01.
After this sale, Sherman directly holds 1,184,327 shares of Orchestra BioMed common stock. The filing notes that the transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025, indicating the sales were scheduled in advance rather than timed discretionarily.
Orchestra BioMed Holdings, Inc. Chief Financial Officer Andrew Taylor Lawrence had 3,076 shares of common stock withheld at a price of $3.98 per share to cover tax obligations tied to vesting restricted stock units. No shares were sold in the market, and he now holds 629,417 shares directly.
Orchestra BioMed Holdings, Inc. director and officer Darren Sherman reported a tax-withholding share disposition tied to RSU vesting. On the transaction date, 4,925 shares of common stock were withheld by the company at $3.98 per share to satisfy tax obligations from vesting restricted stock units.
The footnote clarifies that no shares were sold in the market in connection with this event. After this routine tax-withholding transaction, Sherman directly holds 1,199,327 shares of Orchestra BioMed common stock.
Orchestra BioMed Holdings director Aryeh Jason made a small open-market purchase of company stock. On May 18, 2026, he bought 665 shares of common stock at a weighted average price of about $3.75–$3.76 per share. After this transaction, he directly owns 118,118 shares.
Orchestra BioMed Holdings director Jason Aryeh bought additional company stock in the open market. On May 15, 2026, he purchased 8,971 shares of common stock at a weighted average price of $3.90 per share, through multiple trades priced between $3.70 and $4.03.
Following this transaction, Aryeh directly owns 117,453 shares of Orchestra BioMed common stock. The filing notes that detailed trade-by-trade pricing within this range is available on request from the company, its shareholders, or the SEC staff.
Orchestra BioMed Holdings, Inc. director and officer David P. Hochman reported an open-market purchase of 5,000 shares of Common Stock on May 15, 2026 at a weighted average price of $3.77 per share. Following this purchase, he directly holds 1,059,029 shares of Common Stock.
The filing also lists indirect holdings through several family trusts, including 439,482 shares held by the DPH 2008 Trust and smaller positions held by the NSH 2008 Family Trust and three 2019 trusts.
Orchestra BioMed Holdings director Eric S. Fain, through the Fain Living Trust, bought 20,000 shares of common stock in an open-market purchase on May 14, 2026 at a weighted average price of $4.13 per share. Following this transaction, the trust holds 91,709 shares indirectly.
RTW Investments, LP and affiliated RTW Funds associated with Roderick Wong reported exercising 1,250,032 Pre-Funded Warrants of Orchestra BioMed Holdings, Inc. into common stock at $0.0001 per share on April 27, 2026. The exercise was completed on a cashless basis, with 32 shares withheld to cover the exercise price and 1,250,000 shares issued to the RTW Funds. Following these transactions, the RTW Funds indirectly held 9,556,063 shares of common stock. The Pre-Funded Warrants are immediately exercisable but include a 19.99% beneficial ownership cap, and the reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.
Orchestra BioMed Holdings director and officer Darren Sherman reported a tax-related share disposition linked to restricted stock units. On the vesting of RSUs, the company withheld 33,317 shares of common stock at an effective price of $4.57 per share to cover tax obligations. According to the filing, no shares were sold in the market in connection with this event. After this withholding, Sherman directly holds 1,204,252 shares of Orchestra BioMed common stock.
Orchestra BioMed Holdings, Inc. insider Joshua Aiello, the Principal Accounting Officer, reported a small share disposition tied to taxes, not a market trade. The company withheld 241 shares of Common Stock at $4.57 per share to cover tax obligations from restricted stock unit vesting. After this withholding, Aiello directly holds 18,644 shares of Common Stock.
Orchestra BioMed Holdings director and officer David P. Hochman reported a tax-related share disposition tied to restricted stock units. On the reported date, 32,438 shares of Common Stock at $4.57 per share were withheld by the company to satisfy RSU tax obligations, and no shares were sold in the market.
After this withholding, Hochman directly owns 1,054,029 shares of Common Stock. He also reports additional indirect holdings through several trusts, including 439,482 shares held by the DPH 2008 Trust and smaller positions in other family trusts.
Orchestra BioMed Holdings director and officer David P. Hochman bought 10,000 shares of Common Stock in an open-market purchase at a weighted average price of $4.29 per share. After this transaction, he directly owns 1,086,467 shares, with additional indirect holdings reported through several family trusts.
Aiello Joshua reported acquisition or exercise transactions in a Form 4 filing for OBIO. The filing lists transactions totaling 70,000 shares. Following the reported transactions, holdings were 70,000 shares.
Orchestra BioMed Holdings director and executive Darren Sherman received a stock-based award. On February 12, 2026, he was granted 397,000 shares of common stock in the form of restricted stock units at a price of $0 per share, bringing his directly owned stake to 1,237,569 shares.
The RSUs vest over three years starting from the February 12, 2026 issue date. Vesting occurs in four equal 25% installments at 18, 24, 30, and 36 months, and each unit converts into one share of common stock if he remains in continuous service as President, Chief Operating Officer, and director.
Taylor Andrew Lawrence reported acquisition or exercise transactions in this Form 4 filing.
Orchestra BioMed Holdings Chief Financial Officer granted 181,000 RSUs. On February 12, 2026, CFO Andrew Taylor received an award of 181,000 restricted stock units, each representing a right to one share of common stock at a grant price of $0. The RSUs vest in four equal 25% installments at 18, 24, 30 and 36 months after February 12, 2026, contingent on his continued service. Following this grant, he beneficially owns 632,493 shares of common stock directly.
Hochman David P reported acquisition or exercise transactions in a Form 4 filing for OBIO. The filing lists transactions totaling 504,000 shares. Following the reported transactions, holdings were 1,076,467 shares.
Orchestra BioMed Holdings, Inc. director Chris Cleary reported an automatic share withholding related to equity compensation. On February 5, 2026, the issuer withheld 676 shares of Common Stock at $3.71 per share to cover tax obligations from vesting restricted stock units.
The footnote clarifies that no shares were sold in the market; this was strictly a tax-withholding event handled by the company. After this transaction, Cleary directly beneficially owned 36,901 shares of Orchestra BioMed common stock.
Orchestra BioMed Holdings director and President/COO Darren Sherman reported the vesting of a performance-based stock option for 34,974 shares of common stock. The option carries an exercise price of $2.85 per share and is held directly.
According to the disclosure, this option was originally granted on April 23, 2025. It vests over four years, with 25% scheduled to vest on April 23, 2026, and the remaining 75% vesting in equal installments every three months over the following three years. After the January 28, 2026 transaction, Sherman beneficially owns 34,974 stock options.
Orchestra BioMed Holdings, Inc. reported that its Chief Financial Officer had 8,670 shares of common stock withheld on 12/10/2025 to cover tax obligations from vesting restricted stock units at $4.67 per share.
After this tax withholding, the officer directly beneficially owns 454,945 shares of Orchestra BioMed common stock, and the company states that no shares were sold in the market as part of this transaction.
Orchestra BioMed Holdings, Inc. reported that a director who also serves as Chief Executive Officer and Chairperson had company shares withheld on 12/10/2025 to cover taxes from vesting restricted stock units. The issuer withheld 40,355 shares of Common Stock at $4.67 per share from the reporting person's direct holdings and 3,283 shares at the same price from shares held through the DPH 2008 Trust, with no shares sold in the market.
After these transactions, the reporting person beneficially owns 572,467 shares of Common Stock directly and 439,482 shares indirectly through the DPH 2008 Trust, along with smaller indirect holdings of 2,000 shares in each of three 2019 trusts and 3,140 shares in the NSH 2008 Family Trust.
Orchestra BioMed Holdings, Inc. (OBIO) reported an insider equity transaction by its Chief Financial Officer on 11/25/2025. The filing shows that 3,071 shares of common stock were withheld by the company at a price of $5.35 per share to cover tax withholding obligations arising from the vesting of restricted stock units.
According to the disclosure, no shares were sold in the open market in connection with this event. After this tax-related withholding, the reporting person directly beneficially owns 463,615 shares of Orchestra BioMed common stock.
Orchestra BioMed Holdings, Inc. (OBIO) reported an insider equity transaction involving one of its executives, who is both a director and the President and Chief Operating Officer. On 11/25/2025, the company withheld 40,340 shares of common stock at a price of $5.35 per share to cover tax withholding obligations tied to the vesting of restricted stock units. The filing states that no shares were sold in the open market as part of this event. After this tax-related withholding, the reporting person beneficially owns 846,157 shares of OBIO common stock directly.
Orchestra BioMed Holdings (OBIO) insider trading report: A company director and officer, who serves as Chief Executive Officer and Chairperson, reported an open-market purchase of 5,000 shares of common stock on 11/14/2025. The shares were bought at a weighted average price of $4.07 per share, with individual trades executed between $4.06 and $4.10.
Following this transaction, the insider beneficially owns 612,822 shares directly. Additional indirect holdings are reported through several family trusts, including 442,765 shares held by the DPH 2008 Trust and smaller positions held by other named family trusts.
Orchestra BioMed Holdings, Inc. insider filing reports a tax-related share withholding by a senior executive. On 11/13/2025, the Chief Executive Officer and Chairperson had 3,283 shares of common stock withheld by the company at a price of $4.18 per share to cover tax obligations arising from the vesting of restricted stock units. The filing states that no shares were sold in the market as a result of this vesting and related tax withholding. Following this transaction, the reporting person beneficially owns 607,822 shares directly and 442,765 shares indirectly through the DPH 2008 Trust.